Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.

Published

Journal Article

Using an I.M.S. LifeLink dataset (19 September 2014-11 September 2015), we compared U.S. cardiologist prescribing of the reduced dose of apixaban (2.5 mg) or rivaroxaban (15 mg) to utilization in their corresponding nonvalvular atrial fibrillation registration randomized trials. Of all prescriptions written by cardiologists for these agents, 20.8% of apixaban and 21.7% of rivaroxaban prescriptions were for a reduced dose; corresponding to a 4.4-fold (16.1% absolute) increase in the use of reduced dose apixaban and a 3% relative (0.6% absolute) increase in reduced dose rivaroxaban use vs. their respective registration trials. Further research is needed to better understand appropriate dosing of patients with novel anticoagulants.

Full Text

Duke Authors

Cited Authors

  • Nguyen, E; White, CM; Patel, MR; Fields, LE; Peacock, WF; Crivera, C; Coleman, CI

Published Date

  • July 2016

Published In

Volume / Issue

  • 32 / 7

Start / End Page

  • 1277 - 1279

PubMed ID

  • 27009372

Pubmed Central ID

  • 27009372

Electronic International Standard Serial Number (EISSN)

  • 1473-4877

Digital Object Identifier (DOI)

  • 10.1185/03007995.2016.1170672

Language

  • eng

Conference Location

  • England